Effecty vs Noom

Neither Effecty nor Noom has an FDA warning letter on record. On brand-name tirzepatide pen, Noom costs $11,412 less a year at standing rates: $349 a month against $1,300 a month at Effecty. It is one of two products the two sell at comparable terms.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Effecty / Noom

Effecty logo

Effecty

8.1/10

Noom logo

Noom

7.0/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$170/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026

Neither Effecty nor Noom pays us. Links to them earn nothing. Scores: Effecty 8.1, Noom 7.0. How we are paid

What the record shows

  1. 01

    Neither Effecty nor Noom has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On brand-name tirzepatide pen, Noom costs $11,412 less a year at standing rates: $349 a month against $1,300 a month at Effecty. It is one of two products the two sell at comparable terms.

  4. 04

    Only Effecty lists a price for compounded tirzepatide injection and brand-name semaglutide pen.

  5. 05

    Effecty lists all 50 states. Noom publishes no state list.

  6. 06

    Effecty does not state its cancellation terms; Noom states you can cancel at any time.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Effecty

Noom

Compounded semaglutide injection

$170/moLower

$2,040 a year

$179/mo

$2,148 a year

Brand-name tirzepatide pen

$1,300/mo

$15,600 a year

$349/moLower

$4,188 a year

Compounded tirzepatide injection

$235/mo

$2,820 a year

Not sold or not priced
Brand-name semaglutide pen

$1,300/mo

$15,600 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Clinician visits, coaching
Cancel any time
Not stated
Yes, stated
Minimum term
Month-to-month plan has none; longer plans are paid in advance
Not stated
Refunds
No refunds of subscription fees already paid; all sales are final
Refunds only before a prescription is written; renewal charges are not refunded

Read off each seller’s own pages. Effecty: October 17, 2026. Noom: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Effecty

8.1/10
  • $108 a year less on compounded semaglutide injection
  • Sells compounded tirzepatide injection and brand-name semaglutide pen, which Noom does not price
  • Names no compounding pharmacy

The case for Noom

7.0/10
  • $11,412 a year less on brand-name tirzepatide pen
  • States you can cancel at any time
  • Names no compounding pharmacy
  • Publishes no state list

Scores

Effecty 8.1 · Noom 7.0 out of 10. Six weighted parts.

Value25%

6.1A
vs
B
5.8

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.5A
vs
B
6.5

Accessibility10%

10.0A
vs
B
5.0

Support10%

7.0A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

Effecty vs Noom: questions

Neither Effecty nor Noom has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Effecty, by $108 a year at standing rates. Effecty: $170 a month, about $2,040 a year. Noom: $179 a month, about $2,148 a year.
Effecty does not state its cancellation terms. Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded.
Neither Effecty nor Noom pays us. Links to them earn nothing. Scores: Effecty 8.1, Noom 7.0.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks